These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 15279668)

  • 1. Fatal peripheral neuropathy following FLA chemotherapy.
    Osborne WL; Holyoake TL; McQuaker IG; Parker AN
    Clin Lab Haematol; 2004 Aug; 26(4):295-6. PubMed ID: 15279668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurotoxicity associated with fludarabine and cytosine arabinoside chemotherapy for acute leukemia and myelodysplasia.
    Kornblau SM; Cortes-Franco J; Estey E
    Leukemia; 1993 Mar; 7(3):378-83. PubMed ID: 8445943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia.
    Giles FJ; Cortes JE; Kantarjian HM; O'Brien SM; Estey E; Beran M
    Leuk Res; 2004 Apr; 28(4):353-7. PubMed ID: 15109534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of G-CSF on the in vitro cytotoxicity of cytarabine and fludarabine in the FLAG combination in pediatric acute myeloid leukemia.
    Hubeek I; Litvinova E; Peters GJ; Broekhuizen R; Haarman EG; Huismans DR; Cloos J; Zwaan CM; Fleischhack G; Creutzig U; Kaspers GJ
    Int J Oncol; 2004 Dec; 25(6):1823-9. PubMed ID: 15547723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FLAIE (fludarabine, cytarabine, idarubicin, and etoposide), a four drug induction chemotherapy for adult acute myeloid leukemia: A single center experience.
    Candoni A; Simeone E; Tiribelli M; Malagola M; Russo D; Fanin R
    Am J Hematol; 2009 Oct; 84(10):690-2. PubMed ID: 19731308
    [No Abstract]   [Full Text] [Related]  

  • 6. Fludarabine, cytarabine and topotecan (FLAT) as induction therapy for acute myeloid leukemia in the elderly: a preliminary report.
    Leoni F; Ciolli S; Nozzoli C; Santini V; Fanci R; Rossi Ferrini P
    Haematologica; 2001 Jan; 86(1):104. PubMed ID: 11146581
    [No Abstract]   [Full Text] [Related]  

  • 7. Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients.
    Russo D; Malagola M; de Vivo A; Fiacchini M; Martinelli G; Piccaluga PP; Damiani D; Candoni A; Michielutti A; Castelli M; Testoni N; Ottaviani E; Rondoni M; Pricolo G; Mazza P; Zuffa E; Zaccaria A; Raspadori D; Bocchia M; Lauria F; Bonini A; Avanzini P; Gugliotta L; Visani G; Fanin R; Baccarani M
    Br J Haematol; 2005 Oct; 131(2):172-9. PubMed ID: 16197446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daunorubicin, cytarabine and fludarabine (DAF) for remission induction in relapsed or refractory acute myeloid leukemia. Evaluation of safety, tolerance and early outcome--Polish Adult Leukemia Group (PALG) pilot study.
    Hołowiecki J; Grosicki S; Kyrcz-Krzemien S; Skotnicki AB; Piatkowska-Jakubas B; Warzocha K; Seferynska I; Zdziarska B
    Ann Hematol; 2008 May; 87(5):361-7. PubMed ID: 18074133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients.
    Camera A; Rinaldi CR; Palmieri S; Cantore N; Mele G; Mettivier V; Miraglia E; Mastrullo L; Grimaldi F; Luciano L; Guerriero A; Rotoli B; Ferrara F
    Ann Hematol; 2009 Feb; 88(2):151-8. PubMed ID: 18709502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fludarabine and cytarabine as continuous sequential infusion for elderly patients with acute myeloid leukemia.
    Ferrara F; D'Arco AM; De Simone M; Mele G; Califano C; Pocali B; Danise P; Palmieri S
    Haematologica; 2005 Jun; 90(6):776-84. PubMed ID: 15951290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fludarabine and cytarabine combined chemotherapy followed by transfusion of donor blood stem cells for treating relapse of acute leukaemia after allogeneic haematopoietic stem cell transplantation.
    You Y; Li QB; Chen ZC; Li WM; Xia LH; Zhou H; Zou P
    Chin Med J (Engl); 2008 Sep; 121(18):1770-4. PubMed ID: 19080355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AmBisome treatment of fungal sinusitis in severe immunocompromised patient with acute lymphoblastic leukemia relapsed after autologous peripheral blood transplantation.
    Rokicka M
    Acta Biomed; 2006; 77 Suppl 2():26-7. PubMed ID: 16918064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: a single-center experience.
    Yavuz S; Paydas S; Disel U; Sahin B
    Am J Ther; 2006; 13(5):389-93. PubMed ID: 16988532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Painful peripheral neuropathy associated with voriconazole use.
    Tsiodras S; Zafiropoulou R; Kanta E; Demponeras C; Karandreas N; Manesis EK
    Arch Neurol; 2005 Jan; 62(1):144-6. PubMed ID: 15642862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 19-year-old man with progressive lung infiltrates.
    Tonelli AR; Olson EL
    Cleve Clin J Med; 2009 Nov; 76(11):635-8. PubMed ID: 19884291
    [No Abstract]   [Full Text] [Related]  

  • 16. Fatal dysrhythmia following initiation of lansoprazole during a long-term course of voriconazole.
    Tsubokura M; Miura Y; Itokawa T; Murata K; Takei N; Higaki T; Murashige N; Kami M; Komatsu T
    J Clin Pharmacol; 2011 Oct; 51(10):1488-90. PubMed ID: 21098688
    [No Abstract]   [Full Text] [Related]  

  • 17. Non-anthracycline based remission induction therapy for newly diagnosed patients with acute myeloid leukemia aged 60 or older.
    Bashey A; Liu L; Ihasz A; Medina B; Corringham S; Keese K; Carrier E; Castro JE; Holman P; Lane TA; Hassidim K; Ball ED
    Leuk Res; 2006 Apr; 30(4):503-6. PubMed ID: 16303178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mini-ICE effectively mobilises peripheral blood stem cells after fludarabine-based regimens in acute myeloid leukaemia.
    Mele A; Leopardi G; Sparaventi G; Nicolini G; D'Adamo F; Guiducci B; Barulli S; Malerba L; Stramigioli S; Talevi N; Politi P; Isidori A; Malagola M; Piccaluga P; Visani G
    Eur J Haematol; 2005 Apr; 74(4):277-81. PubMed ID: 15777338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML).
    Vehreschild JJ; Böhme A; Buchheidt D; Arenz D; Harnischmacher U; Heussel CP; Ullmann AJ; Mousset S; Hummel M; Frommolt P; Wassmer G; Drzisga I; Cornely OA
    J Infect; 2007 Nov; 55(5):445-9. PubMed ID: 17822770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fludarabine, cytarabine, and mitoxantrone (FLAM) for the treatment of relapsed and refractory adult acute lymphoblastic leukemia. A phase study by the Polish Adult Leukemia Group (PALG).
    Giebel S; Krawczyk-Kulis M; Adamczyk-Cioch M; Jakubas B; Palynyczko G; Lewandowski K; Dmoszynska A; Skotnicki A; Nowak K; Holowiecki J;
    Ann Hematol; 2006 Oct; 85(10):717-22. PubMed ID: 16832677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.